Accelerated anxiosomatic circuit TMS: An open-label pilot study in Chinese participants with a treatment-resistant anxiety-related disorder

作者：HuiRu Cui, Ryan Webler, Lihua Xu, Zhenying Qian, Yingying Tang, Tianhong Zhang, Chunbo Li, Shan Siddiqi, Jijun Wang · 发表于：Brain stimulation · 年份：2025 · DOI：10.1016/j.brs.2025.05.102 · 被引用次数：2 · 研究领域：Perfectionism, Procrastination, Anxiety Studies、Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes

Anxiety-related disorders are extremely common and frequently disabling [1]. Current treatments are associated with high drop-out and non-response rates, necessitating new approaches. Transcranial magnetic stimulation (TMS) is now FDA-cleared for anxiety comorbid with major depressive disorder (MDD). However, the optimal anxiety target remains undefined, and TMS applied to the most common target (i.e., left dorsolateral prefrontal cortex, dlPFC) may increase anxiety in approximately 20 % of patients [2].